NCT07690332 A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α(FRα) Status NOT_YET_RECRUITING Phase N/A
NCT07667192 Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer Status RECRUITING Phase N/A
NCT07648745 Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer Status COMPLETED Phase PHASE2
NCT07591831 Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07586826 Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors Status RECRUITING Phase PHASE2
NCT07545460 A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer Status NOT_YET_RECRUITING Phase PHASE3
NCT07489300 Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07472140 PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer Status RECRUITING Phase PHASE2/PHASE3
NCT07432594 Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT07322094 CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer Status RECRUITING Phase PHASE1/PHASE2
NCT07044349 Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Status NOT_YET_RECRUITING Phase PHASE2
NCT06994195 A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) Status RECRUITING Phase PHASE3
NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Status RECRUITING Phase PHASE2
NCT06856499 Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer Status RECRUITING Phase PHASE1
NCT06824467 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Status RECRUITING Phase PHASE3
NCT06792552 A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors Status RECRUITING Phase PHASE1
NCT06787612 Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Status RECRUITING Phase PHASE2
NCT06710548 REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors Status RECRUITING Phase NA
NCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine Status RECRUITING Phase PHASE2
NCT06545617 A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer Status WITHDRAWN Phase PHASE1/PHASE2